Day: September 20, 2021

Radisson Collection Hotel, Palazzo Touring Club Milan guest room designRadisson Collection Hotel, Palazzo Touring Club Milan guest room designRadisson Collection Hotel, Palazzo Touring Club Milan restaurantRadisson Collection Hotel, Palazzo Touring Club Milan restaurantRadisson Collection Hotel, Palazzo Touring Club Milan suiteRadisson Collection Hotel, Palazzo Touring Club Milan suiteRadisson Collection Hotel, Palazzo Touring Club Milan exteriorRadisson Collection Hotel, Palazzo Touring Club Milan exteriorRadisson Collection Hotel, Palazzo Touring Club Milan lobby areaRadisson Collection Hotel, Palazzo Touring Club Milan lobby areaRadisson Collection Hotel, Palazzo Touring Club Milan opens its doors in the heart of Milan Set in an iconic building at the...

– Ms. Corzo brings a 25+ year successful track record in biopharma, excelling in oncology drug development with Takeda, Sanofi Genzyme, and Eli Lilly – BEDMINSTER, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today announced the nomination of Kathryn Penkus Corzo to stand for election to the Company’s Board of Directors at its 2021 Annual Meeting of Stockholders, scheduled for November 1, 2021. Ms. Corzo is currently partner at Takeda Ventures, Inc. and previously Head of Oncology Cell Therapy Development at Takeda Pharmaceuticals, a global, values-based, R&D-driven biopharmaceutical...

DEVON, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will participate in a fireside chat during the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 11:20 a.m. ET. Investors interested in arranging a virtual meeting with the Company’s management during the conference should contact the Cantor conference coordinator. A webcast of the fireside chat will be available under the Events & Webcasts tab of the Investors section of the Zynerba website at www.zynerba.com. An archived replay will be available on the Company’s website following the...

VANCOUVER, British Columbia, Sept. 20, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF) (FRANKFURT: AGW) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it plans to file a pre-IND (Investigational New Drug) meeting request with the U.S. Food and Drug Administration (U.S. FDA) for an NP-120 (Ifenprodil) Phase 2 chronic cough study. Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B). The decision to expand its Ifenprodil research program was based on positive trending interim data received by the Company from the chronic cough part of its 20-patient Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough study being conducted in Australia and New Zealand. The interim...

Second Phase 2 trial of omilancor in Crohn’s disease (CD), expected to initiate in 2021 Awarded a $3 million NIH R01 grant from the U.S. National Institute of Diabetes and Digestive and Kidney Diseases to fund this study BLACKSBURG, Va., Sept. 20, 2021 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral small-molecule therapeutics for patients with autoimmune diseases, today announced a research collaboration with the Icahn School of Medicine at Mount Sinai to conduct a Phase 2 trial of omilancor, Landos’ novel, orally administered, gut-restricted LANCL2 agonist, in patients with moderate-to-severe Crohn’s disease (CD). “Entering this partnership with the Icahn School of Medicine at Mount Sinai highlights our...

Fast-Acting And Long-Lasting Sleep Formula Promotes Quicker Sleep Onset And A Restful NightPLUS Dual Action Sleep GummiesPlus Products Reveals Dual Action Sleep gummies featuring first combined fast acting, long lasting formulationSAN MATEO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) — Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) (the “Company” or “PLUS”), a cannabis and hemp-branded products company in California, today announced the launch of its Dual Action Sleep gummies, featuring a two part formulation that starts working in eight minutes, while also lasting throughout the night. Highlights:Two new gummies, Dual Action Sleep Cloudberry and Dual Action Sleep Lychee feature the all-new Dual Action Formula. The new and improved Dual Action formulation uses fast acting nano-emulsion that starts the bedtime process...

LYR-210 Pharmacokinetic Study Chosen as a Top Clinical Abstract at ARS WATERTOWN, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) — Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that four abstracts highlighting LYR-210 results in chronic rhinosinusitis and the XTreo™ platform have been selected for presentations at the upcoming 28th Congress of European Rhinologic Society (ERS) and the 67th Annual Meeting of the American Rhinologic Society (ARS), held September 26-30 and October 1-2, 2021 respectively. New LYR-210 data from the LANTERN 6-month follow-up study and recently completed pharmacokinetic study, will be the...

EDEN PRAIRIE, Minn., Sept. 20, 2021 (GLOBE NEWSWIRE) — Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced that the Company will be added to the Russell Microcap® Index, effective after the U.S. market opens today, September 20, 2021. The Russell Microcap Index measures the microcap segment of the U.S. equity market, consisting of the smallest 1,000 securities in the small-cap Russell 2000® Index, plus the next 1,000 smallest eligible securities by market cap. The Index is completely reconstituted annually to ensure new and growing equities are reflected and companies continue to reflect appropriate capitalization and value characteristics. “We are honored and thrilled to...

WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 8:40 a.m. ET. The conference will be held in a virtual meeting format. The event will be available via live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website at https://investors.apellis.com/events-and-presentations. A replay of the webcast will be available for 90 days following the event. About ApellisApellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing...

MONTREAL, Sept. 20, 2021 (GLOBE NEWSWIRE) — TOMAGOLD CORPORATION (TSXV: LOT) (OTCQB: TOGOF) (“TomaGold” or the “Corporation”) is pleased to provide an update on the drilling program on its wholly-owned Obalski property, located 3 km south of Chibougamau. The program, which started on July 10, 2021, has been expanded from 10,000 metres to 11,500 metres of drilling following reassessment of the drill targets. Drilling has been temporarily paused and will resume in October. As at September 6, 2021, eight holes and two hole extensions had been drilled, for a total of 4,693 metres. A total of 751 samples have been collected and sent to the ALS Global laboratory in Val-d’Or for analysis, of which 135 will be analysed by both fire assay and cyanidation for the purpose of comparing and validating whether there is a significant difference...